Biofrontera AG

Biofrontera AG's next confirmed earnings release is scheduled for November 19, 2026.

As of March 31, 2026, Biofrontera AG has 6.08M shares outstanding.

As of March 31, 2026, Biofrontera AG maintains a current ratio of 2.96, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.79, indicating elevated leverage, while an interest coverage ratio of -147.69 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Biofrontera AG posted a return on equity (ROE) of 14.50, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 9.95, measuring how efficiently the asset base is converted into earnings. The company generates approximately 134,305.88 in revenue per employee across its workforce of 85.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.28 indicates how many times Biofrontera AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Biofrontera AG recorded 568,000.00 in income tax expense. The company reported a pretax loss of -2.87M and 2.61M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Biofrontera AG's stock has declined approximately 79.02% over the past 52 weeks.

Over the twelve months ended March 31, 2026, Biofrontera AG generated 11.42M in revenue and converted that into 2.61M in net income, yielding earnings per share of -0.56. EBITDA reached -2.36M, while operating income came in at -2.36M.

As of March 31, 2026, Biofrontera AG holds 5.69M in cash and equivalents against 1.16M in total debt, resulting in a net debt position of -4.48M. Total book value stands at 17.10M, with working capital of 8.77M providing operational flexibility.

Over the twelve months ended March 31, 2026, Biofrontera AG posted a gross margin of 88.66, reflecting its pricing power and cost economics. The operating margin of -20.71 and net profit margin of 22.83 provide insight into operational efficiency.

Biofrontera AG's most recent stock split took place on May 14, 2024.